Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells 3,600 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $238.81, for a total value of $859,716.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $31,045.30. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR traded down $1.05 on Thursday, hitting $235.95. 391,825 shares of the company were exchanged, compared to its average volume of 439,210. United Therapeutics Co. has a 1-year low of $204.44 and a 1-year high of $261.54. The stock’s 50 day moving average price is $233.36 and its 200 day moving average price is $228.79. The company has a current ratio of 4.41, a quick ratio of 4.28 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $11.10 billion, a P/E ratio of 11.89 and a beta of 0.52.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. The firm had revenue of $614.70 million for the quarter, compared to analyst estimates of $575.01 million. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The business’s quarterly revenue was up 25.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.67 earnings per share. Sell-side analysts predict that United Therapeutics Co. will post 23.45 EPS for the current year.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of UTHR. Norges Bank purchased a new position in shares of United Therapeutics during the 4th quarter valued at approximately $100,519,000. Avidity Partners Management LP purchased a new position in shares of United Therapeutics in the fourth quarter valued at approximately $52,158,000. Comerica Bank increased its position in shares of United Therapeutics by 2,697.2% during the third quarter. Comerica Bank now owns 156,587 shares of the biotechnology company’s stock worth $35,368,000 after purchasing an additional 150,989 shares in the last quarter. Victory Capital Management Inc. raised its stake in United Therapeutics by 309.7% in the 4th quarter. Victory Capital Management Inc. now owns 134,162 shares of the biotechnology company’s stock valued at $29,501,000 after purchasing an additional 101,419 shares during the last quarter. Finally, TD Asset Management Inc raised its holdings in United Therapeutics by 1,066.4% in the 4th quarter. TD Asset Management Inc now owns 82,951 shares of the biotechnology company’s stock valued at $18,240,000 after acquiring an additional 75,839 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

UTHR has been the subject of several recent analyst reports. Leerink Partnrs reaffirmed an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. The Goldman Sachs Group upgraded United Therapeutics from a “sell” rating to a “neutral” rating and raised their price objective for the company from $213.00 to $215.00 in a research report on Monday, February 12th. Wells Fargo & Company boosted their price target on United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a report on Thursday, March 7th. SVB Leerink started coverage on United Therapeutics in a research note on Monday, February 5th. They issued an “outperform” rating and a $330.00 price objective on the stock. Finally, StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 11th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $294.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.